Nia Therapeutics has published peer-reviewed data in Brain Stimulation on the first in vivo validation of its wireless, implantable brain-computer interface, Smart Neurostimulation System (SNS).
The platform is designed for closed-loop neurostimulation brain implant applications for memory disorders.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is capable of recording neural activity from 60 channels spanning four distinct brain regions. This offers a broader sensing capability than currently available devices, aiming to address the distributed nature of memory that relies on coordinated dynamics across multiple neural networks rather than a single site.
Preclinical validation was conducted through a chronic study involving three sheep, where the SNS displayed a stable performance in several core functions.
In neural-state decoding, machine-learning classifiers were able to distinguish movement from stillness with an area under the curve (AUC) of 0.92 to 0.98, maintaining stability through the implantation period.
For programmable neuromodulation, systematic adjustments to stimulation parameters resulted in dose-dependent changes in both alpha-band (8Hz–12Hz) and gamma-band (78Hz–82Hz) neural activity, confirming reliable modulation of physiological signals.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBiocompatibility was demonstrated as histological analysis showed no adverse tissue response.
Nia Therapeutics co-founder and CEO Michael Kahana said: “Most brain implants were developed for conditions in which a localised abnormal signal drives symptoms.
“Decades of research show that memory depends on coordinated activity across distributed networks. The SNS was engineered to detect these patterns and respond with personalised stimulation.”
The SNS is based on research funded by the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH).
Previous human studies using externalised systems showed that machine-learning models could predict memory performance and that brief, targeted stimulation improved delayed recall by approximately 20%.
